CLOs on the Move

California Cryobank Inc.

www.cryobank.com

 
California Cryobank Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Los Angeles, CA. To find more information about California Cryobank Inc., please visit www.cryobank.com
  • Number of Employees: 50K-100K
  • Annual Revenue: $1-10 Million
  • www.cryobank.com
  • 11915 La Grange Ave
    Los Angeles, CA USA 90025-5213
  • Phone: 310.443.5244

Executives

Name Title Contact Details

Similar Companies

Autonomic Technologies

Autonomic Technologies is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company`s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache.

Va Urology Ctr

Va Urology Ctr is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Henrico, VA. To find more information about Va Urology Ctr, please visit www.uro.com

Vita-Med Labs

Vita-Med Labs is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Nanoscope Therapeutics

Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.

Aratana Terapeutics

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of prescription medicines for pets in the United States and Europe. It develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a potent and selective ghrelin agonist for the stimulation of appetite in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension to manage post-operative pain in cats and dogs following surgery. The company was founded in 2010 and is headquartered in Kansas City, Kansas.